## MCK: McKesson Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.00 indicates fundamental undervaluation. Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-6.2% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($770.06)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Sands Capital Management LLC Buys 54,117 Shares of McKesson Corporation $MCK**
- Source: MarketBeat | 20251204T131001 | Bullish | Relevance: 100%
- Sands Capital Management LLC significantly increased its stake in McKesson Corporation, purchasing 54,117 additional shares, bringing its total to 145,867 shares valued at approximately $106.9 million. Other major institutions like Norges Bank, Nuveen, Arrowstreet, Wellington, and Boston Partners also accumulated substantial positions, indicating strong institutional confidence in McKesson. The company recently reported better-than-expected earnings, declared a quarterly dividend, and holds a "Moderate Buy" consensus rating from analysts with an $887.69 price target.

**2. McKesson Corporation (MCK) Stock Today: Price Drop, Oncology Push and 2026 Outlook as of December 3, 2025**
- Source: ts2.tech | 20251203T230808 | Bullish | Relevance: 100%
- McKesson Corporation (MCK) experienced a stock price drop of nearly 3% on December 3, 2025, closing at $805.37, despite being a strong performer in U.S. healthcare throughout the year. The pullback is attributed to profit-taking, institutional portfolio adjustments, and investors processing new guidance and oncology initiatives. The company is actively reshaping its portfolio by spinning off its Medical-Surgical Solutions segment and focusing on oncology, specialty drugs, and tech-enabled services, with analysts generally bullish on its long-term prospects.

**3. McKesson Corporation pushes for biopharma collaboration in cancer care**
- Source: Traders Union | 20251203T025213 | Bullish | Relevance: 100%
- McKesson Corporation advocates for increased collaboration within the biopharma industry to enhance cancer care. The company emphasizes the necessity for biopharma companies to partner with community oncologists to support policies that protect access and foster innovation in the medical field amidst rapid policy changes.

**4. Why Is McKesson (MCK) Down 5.2% Since Last Earnings Report?**
- Source: www.sharewise.com | 20251205T182737 | Somewhat-Bullish | Relevance: 100%
- McKesson (MCK) shares have dropped 5.2% since its last earnings report, underperforming the S&P 500, despite beating EPS estimates for Q2 fiscal 2026. The company's revenues missed expectations, though they grew year-over-year, and McKesson has raised its fiscal 2026 EPS guidance. Estimates for the stock have been broadly trending downward in the past month.

**5. American Century Companies Inc. Has $10.05 Million Position in McKesson Corporation $MCK**
- Source: MarketBeat | 20251205T084055 | Bullish | Relevance: 100%
- American Century Companies Inc. increased its stake in McKesson Corporation (NYSE:MCK) by 16.0% during the second quarter, bringing its total holdings to 13,718 shares valued at $10.05 million. This move is part of several institutional and analyst actions, including price objective increases and dividend announcements, reflecting ongoing interest in the healthcare services provider. McKesson recently reported strong quarterly earnings, surpassing analyst estimates, and announced a quarterly dividend of $0.82 per share.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-10 | Wells Fargo | $914 | $816 | +12% |
| 2025-11-06 | UBS | $980 | $920 | +7% |
| 2025-11-06 | Baird | $927 | $873 | +6% |
| 2025-11-06 | Morgan Stanley | $916 | $857 | +7% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-10 | Wells Fargo | main | Equal-Weight |
| 2025-11-06 | UBS | main | Buy |
| 2025-11-06 | Baird | main | Outperform |
| 2025-11-06 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 1 ($0.28M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 42.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 9.8% (-0.3%)
- Blackrock Inc.: 9.2% (+0.4%)
- State Street Corpora: 4.7% (+0.9%)
- JPMORGAN CHASE & CO: 4.5% (+16.0%)
- Massachusetts Financ: 3.2% (-1.5%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-6.2% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Analyst target momentum: 4 raises (avg +8%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.00 indicates undervaluation relative to growth. Balance sheet: $2.3B free cash flow. Analyst sentiment positive (4 raises, avg +8%). Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $103.0B |
| Beta | 0.38 |
| 52W Range | $565.75 - $895.58 |
| Short Interest | 1.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.00 |
| Forward P/E | 18.5 |
| Current P/E | 20.9 |
| YoY Growth | 13.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -0.9% to -7.1% (-6.2% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 11.1pp (needs >4.0% for momentum thesis). AM_20 at -4.9% indicates price below own 20MA trend. Underperforming sector by 4.8pp, stock-specific weakness. Long-term uptrend intact (above SMA200 at 1.12x) but short-term weakness (below SMA20). MACD histogram bearish (-10.15), momentum weakening. RSI neutral at 41. OFD pattern: -SUL (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -7.10% (CS: 4) | Weak |
| RSI_14 | 41.0 | Neutral |
| MACD Histogram | -10.15 | Bearish |
| vs SMA20 | 0.950x | Below |
| vs SMA50 | 0.995x | Below |
| vs SMA200 | 1.118x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $808.62
- **Stop Loss:** $770.06 (4.8% risk)
- **Target:** $885.74 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 12
- **Position Value:** $9,703.44
- **Portfolio %:** 9.70%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with balanced risk appetite. VIX near 15th percentile of 52-week range signals calm conditions, while modest yield curve steepening (54bps 10Y-3M) suggests healthy growth expectations. Breadth at 52% indicates selective participation rather than broad-based momentum.*

### Earnings

**Next:** 2026-02-04 (Est: $9.28)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $9.05 | $9.86 | +8.9% |
| 2025Q2 | $8.15 | $8.26 | +1.4% |
| 2025Q1 | $9.83 | $10.12 | +3.0% |
| 2024Q4 | $7.99 | $8.03 | +0.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*